Prof. Mohammad Gholinejad | Organic Chemistry | Best Researcher Award

Published on by Chemistry Awards

Prof. Mohammad Gholinejad | Organic Chemistry | Best Researcher Award 

Prof. Mohammad Gholinejad | Organic Chemistry | Associate Professor of Chemistry at IASBS, Iran

Dr. Mohammad Gholinejad is an Associate Professor of Organic Chemistry at the Institute for Advanced Studies in Basic Sciences (IASBS), Iran, he specializes in catalysis, organic synthesis, and nanomaterials. He completed his Ph.D. from Shiraz University under the supervision of Prof. Habib Firouzabadi, focusing on palladium, copper, iron, and silver nanoparticles in carbon-carbon and carbon-heteroatom bond formation. He undertook a sabbatical at the University of Alicante, Spain, with Prof. Carmen Najera, working on phosphane-free Suzuki-Miyaura coupling. With an h-index of 36 and over 3,400 citations, Dr. Gholinejad has significantly contributed to the field of homogeneous and heterogeneous catalysis. His expertise extends to TGA, GC, NMR, and XPS techniques. He actively teaches advanced organic chemistry and heterocyclic chemistry, mentoring numerous students. His work bridges fundamental research and practical applications, making him a key figure in modern catalysis.

Professional Profile :                       

Google Scholar

Orcid

Scopus

Summary of Suitability for Award:

Dr. Mohammad Gholinejad is a highly accomplished researcher in the field of organic chemistry, specializing in catalysis, nanoparticle applications, and green chemistry. With an h-index of 36 and over 3,400 citations, his research contributions have significantly impacted the scientific community. His expertise in palladium, copper, iron, and silver nanoparticles for carbon-carbon and carbon-heteroatom bond formation reactions has led to innovative methodologies that are both efficient and environmentally friendly. He has held a prestigious sabbatical position at the University of Alicante, Spain, and currently serves as an Associate Professor at the Institute for Advanced Studies in Basic Sciences (IASBS). His extensive publication record, leadership in advanced organic chemistry courses, and hands-on experience with instrumental techniques further highlight his research excellence. Given his outstanding research output, impact on organic synthesis, and contributions to sustainable chemistry, Dr. Gholinejad is a highly suitable candidate for the “Best Researcher Award.” His work exemplifies innovation, academic excellence, and real-world application, making him a strong contender for this recognition.

🎓Education:

Dr. Mohammad Gholinejad obtained his Ph.D. in Organic Chemistry from Shiraz University, Iran (2008-2012), where he investigated carbon-carbon and carbon-heteroatom bond formation using metal nanoparticles. His research introduced efficient catalytic systems for environmentally friendly organic transformations. His M.Sc. in Organic Chemistry (2006-2008) at Shiraz University focused on phosphinite ligands in organic synthesis. He earned his B.Sc. in Applied Chemistry from the University of Tabriz (2002-2006). In 2010, Dr. Gholinejad pursued a sabbatical at the University of Alicante, Spain, under Prof. Carmen Najera, working on phosphane-free Suzuki-Miyaura coupling. His academic journey has shaped his expertise in catalytic systems, green chemistry, and ligand design. His research integrates experimental and theoretical chemistry, leading to numerous high-impact publications. His strong analytical background and mastery of spectroscopic techniques have enhanced his contributions to organic synthesis and catalysis, making him a leading researcher in the field.

🏢Work Experience:

Dr. Mohammad Gholinejad is an Associate Professor at IASBS, Iran, where he has been engaged in research and teaching for over a decade. His teaching portfolio includes Advanced Organic Chemistry (Structure and Mechanisms), Organic Reactions and Synthesis, Heterocyclic Chemistry, and New Discussions in Organic Chemistry. His research focuses on designing novel catalytic systems using palladium, copper, and iron nanoparticles for sustainable organic transformations. He has extensive expertise in TGA, GC, NMR, and XPS, essential for analyzing catalytic reactions. During his sabbatical at the University of Alicante, Spain, he collaborated with Prof. Carmen Najera on phosphane-free Suzuki-Miyaura coupling in aqueous media. His work has led to numerous high-impact publications in prestigious journals. He actively supervises M.Sc. and Ph.D. students, contributing to the development of young researchers. His role at IASBS has been instrumental in advancing research on green and heterogeneous catalysis.

🏅Awards: 

Dr. Mohammad Gholinejad has received numerous prestigious awards and honors in recognition of his outstanding contributions to the field of organic chemistry. His work in catalysis and green chemistry has been widely acknowledged, earning him accolades from both national and international scientific communities. He has been recognized for his high-impact publications in reputed journals, reflecting his significant influence in the domain of sustainable chemical methodologies. His sabbatical at the University of Alicante, Spain, is a testament to his global research collaborations and expertise. Additionally, he has been honored with research grants and funding awards, enabling him to advance studies in nanoparticle catalysis and environmentally friendly synthetic processes. As an Associate Professor at the Institute for Advanced Studies in Basic Sciences (IASBS), he has received institutional recognition for his exemplary research, mentorship, and contributions to academic excellence. His achievements establish him as a leading researcher in organic synthesis and catalysis.

🔬Research Focus:

Dr. Mohammad Gholinejad’s research primarily focuses on the development of novel catalytic systems for organic transformations, particularly using palladium, copper, iron, and silver nanoparticles. His work has significantly advanced carbon-carbon and carbon-heteroatom bond formation reactions, leading to more efficient and environmentally sustainable chemical processes. By integrating nanotechnology with catalysis, he has contributed to the design of innovative, recyclable catalytic systems that minimize waste generation and reduce reliance on hazardous reagents. His expertise extends to green chemistry, where he develops eco-friendly methodologies for organic synthesis, emphasizing the use of non-toxic solvents, reusable catalysts, and sustainable reaction conditions. His pioneering research in heterogeneous catalysis has implications for pharmaceuticals, materials science, and industrial chemistry. Additionally, his work on functionalized nanomaterials has potential applications in energy storage and biomedical fields. Through high-impact publications and global collaborations, Dr. Gholinejad continues to drive advancements in synthetic methodologies, enhancing the efficiency and sustainability of modern chemistry.

Publication Top Notes:

Title: Magnetite (Fe₃O₄) Nanoparticles‐Catalyzed Sonogashira–Hagihara Reactions in Ethylene Glycol under Ligand‐Free Conditions
Authors: H. Firouzabadi, N. Iranpoor, M. Gholinejad, J. Hoseini
Citations: 174
Year: 2011

Title: One‐Pot Thioetherification of Aryl Halides Using Thiourea and Alkyl Bromides Catalyzed by Copper (I) Iodide Free from Foul‐Smelling Thiols in Wet Polyethylene Glycol (PEG 200)
Citations: 164

Title: Highly Efficient Three-Component Coupling Reaction Catalyzed by Gold Nanoparticles Supported on Periodic Mesoporous Organosilica with Ionic Liquid Framework
Citations: 154

Title: Palladium Nanoparticles Supported on Agarose as Efficient Catalyst and Bioorganic Ligand for C–C Bond Formation via Solventless Mizoroki–Heck Reaction and Sonogashira–Hagihara Reaction
Citations: 107

Title: Synthesis and Characterization of Magnetic Copper Ferrite Nanoparticles and Their Catalytic Performance in One-Pot Odorless Carbon-Sulfur Bond Formation Reactions
Citations: 98

Title: 2-Aminophenyl Diphenylphosphinite as a New Ligand for Heterogeneous Palladium-Catalyzed Heck–Mizoroki Reactions in Water in the Absence of Any Organic Co-Solvent
Citations: 93

Title: Copper Nanoparticles Supported on Agarose as a Bioorganic and Degradable Polymer for Multicomponent Click Synthesis of 1,2,3-Triazoles under Low Copper Loading in Water
Citations: 89

Title: Nitro Group Reduction and Suzuki Reaction Catalysed by Palladium Supported on Magnetic Nanoparticles Modified with Carbon Quantum Dots Generated from Glycerol and Urea
Citations: 83

Title: Copper Nanoparticles Supported on Starch Microparticles as a Degradable Heterogeneous Catalyst for Three-Component Coupling Synthesis of Propargylamines
Citations: 83

Title: Palladium Nanoparticles Supported on Agarose-Functionalized Magnetic Nanoparticles of Fe₃O₄ as a Recyclable Catalyst for C–C Bond Formation via Suzuki–Miyaura, Heck–Mizoroki Reactions
Citations: 77

Title: Recyclable Palladium-Catalyzed Sonogashira–Hagihara Coupling of Aryl Halides Using 2-Aminophenyl Diphenylphosphinite Ligand in Neat Water under Copper-Free Condition
Citations: 77

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Dr. Xufen Yu | Medicinal Chemistry | Associate Professor at Fudan University, China

Dr. Xufen Yu is an Associate Professor in the Department of Medicinal Chemistry at Fudan University’s School of Pharmacy. She specializes in drug discovery, chemical biology, and targeted protein degradation, particularly in cancer therapeutics. Before joining Fudan University, she was an Instructor and Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, where she contributed significantly to pharmacological sciences. Dr. Yu has also held postdoctoral positions at Purdue University and the University of Hawaii at Hilo. She holds a Ph.D. from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry. Her research has led to numerous high-impact publications in journals such as Journal of Medicinal Chemistry, Oncogene, and Nature Cancer. With extensive expertise in PROTAC-based therapeutics and epigenetic regulation, Dr. Yu continues to make significant contributions to the field of medicinal chemistry and targeted cancer therapy.

Professional Profile : 

Google Scholar

Orcid

Scopus  

Summary of Suitability for Award:

Dr. Xufen Yu is an exceptionally accomplished researcher in medicinal chemistry, with significant contributions to drug discovery, targeted protein degradation, and epigenetics. Her extensive academic background, including a Ph.D. from the Chinese Academy of Sciences and postdoctoral research at prestigious institutions such as Purdue University and the Icahn School of Medicine at Mount Sinai, demonstrates her expertise in chemical biology and small-molecule therapeutics. She has consistently advanced the field through high-impact publications, innovative research, and groundbreaking discoveries in PROTACs and DUBTACs, which have transformed targeted cancer therapy.  Given her outstanding achievements, innovative research, and contributions to medicinal chemistry, Dr. Xufen Yu is highly suitable for the “Best Researcher Award”. Her pioneering work in targeted protein degradation, combined with her international recognition and research excellence, makes her a strong candidate. Her research has not only advanced scientific knowledge but also holds significant promise for therapeutic applications, reinforcing her eligibility for this distinguished honor.

🎓Education:

Dr. Xufen Yu earned her Ph.D. in Organic Chemistry from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, in 2011. Her doctoral research focused on synthetic organic chemistry and drug discovery. Prior to that, she completed her undergraduate studies at Anhui University, Hefei, China, earning a Bachelor’s degree in Chemistry in 2006. With a strong academic foundation, Dr. Yu developed expertise in medicinal chemistry, chemical biology, and targeted protein degradation. Her educational journey equipped her with extensive knowledge of molecular design, synthetic methodologies, and structure-activity relationship studies, laying the groundwork for her future contributions to pharmacological sciences. Her rigorous training in organic synthesis and chemical biology has driven her impactful research in developing novel therapeutics, particularly in targeted protein degradation and epigenetic regulation.

🏢Work Experience:

Dr. Xufen Yu has had a distinguished career in academia and research, with extensive postdoctoral and faculty experience. She is currently an Associate Professor in the Department of Medicinal Chemistry at Fudan University, Shanghai, China. Before joining Fudan, she was an Instructor in the Department of Pharmacological Science at the Icahn School of Medicine at Mount Sinai, New York (2021–2022), following a postdoctoral fellowship at the same institution from 2017 to 2020. She also worked as a postdoctoral fellow in Chemistry at Purdue University (2013–2014) and in Pharmaceutical Science at the University of Hawaii at Hilo (2011–2013). Through these roles, she has contributed significantly to medicinal chemistry, focusing on drug discovery, targeted protein degradation, and cancer therapeutics. Her work across multiple prestigious institutions reflects her expertise in interdisciplinary research, integrating chemistry and pharmacology to develop novel small-molecule therapeutics.

🏅Awards: 

Dr. Xufen Yu has been recognized for her outstanding contributions to medicinal chemistry and drug discovery. She has received multiple awards and research grants for her pioneering work in targeted protein degradation and epigenetics. Her innovative research has been acknowledged with prestigious fellowships and funding from institutions such as the National Institutes of Health (NIH) and the Chinese Academy of Sciences. Additionally, she has been honored for her significant publications in high-impact journals, receiving accolades for breakthrough studies on PROTACs and epigenetic regulators in cancer therapy. Her commitment to scientific excellence has led to invitations as a speaker at international conferences, where she has shared her expertise in medicinal chemistry. Dr. Yu’s contributions have been instrumental in advancing chemical biology and therapeutic discovery, making her a well-respected figure in her field.

🔬Research Focus:

Dr. Xufen Yu’s research focuses on the development of novel therapeutic strategies targeting disease-related proteins, particularly in cancer and metabolic disorders. Her expertise lies in targeted protein degradation, including the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) and DUBTACs (Deubiquitinase Targeting Chimeras). She has explored epigenetic regulation in cancer therapy, investigating how small molecules can modulate oncogenic transcription factors and chromatin regulators. Her work also includes studying the role of ubiquitin-proteasome and autophagy systems in disease mechanisms, aiming to develop highly selective small-molecule therapeutics. Through interdisciplinary approaches combining medicinal chemistry, chemical biology, and pharmacology, she has contributed to advancing targeted cancer treatments. Dr. Yu’s research has led to the discovery of several potent and selective degraders for oncogenic proteins such as EZH2, WDR5, and USP7, paving the way for new treatment modalities in oncology.

Publication Top Notes:

Macrocyclic drugs and synthetic methodologies toward macrocycles
Authors: X Yu, D Sun
Citations: 276
Year: 2013

Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism
Authors: AJ Bott, J Shen, C Tonelli, L Zhan, N Sivaram, YP Jiang, X Yu, V Bhatt, …
Citations: 155
Year: 2019

Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders
Authors: M Cheng, X Yu, K Lu, L Xie, L Wang, F Meng, X Han, X Chen, J Liu, …
Citations: 151
Year: 2020

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Authors: J Wang, X Yu, W Gong, X Liu, KS Park, A Ma, YH Tsai, Y Shen, T Onikubo, …
Citations: 134
Year: 2022

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Authors: X Yu, D Li, J Kottur, Y Shen, HS Kim, KS Park, YH Tsai, W Gong, J Wang, …
Citations: 103
Year: 2021

Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders
Authors: Y Shen, G Gao, X Yu, H Kim, L Wang, L Xie, M Schwarz, X Chen, …
Citations: 84
Year: 2020

Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery
Authors: AM Chiarella, KV Butler, BE Gryder, D Lu, TA Wang, X Yu, S Pomella, …
Citations: 77
Year: 2020

Cationic Palladium Complex Catalyzed Diastereo-and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates
Authors: X Yu, X Lu
Citations: 57
Year: 2009

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B
Authors: J Xu, X Yu, TC Martin, A Bansal, K Cheung, A Lubin, E Stratikopoulos, …
Citations: 51
Year: 2021

Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders
Authors: X Yu, J Xu, L Xie, L Wang, Y Shen, KM Cahuzac, X Chen, J Liu …
Citations: 42
Year: 2021